BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 33394321)

  • 1. Transition rates to cirrhosis and liver cancer by age, gender, disease and treatment status in Asian chronic hepatitis B patients.
    Liu M; Tseng TC; Jun DW; Yeh ML; Trinh H; Wong GLH; Chen CH; Peng CY; Kim SE; Oh H; Kwak MS; Cheung M; Toyoda H; Hsu YC; Jeong JY; Yoon EL; Ungtrakul T; Zhang J; Xie Q; Ahn SB; Enomoto M; Shim JJ; Cunningham C; Jeong SW; Cho YK; Ogawa E; Huang R; Lee DH; Takahashi H; Tsai PC; Huang CF; Dai CY; Tseng CH; Yasuda S; Kozuka R; Li J; Wong C; Wong CC; Zhao C; Hoang J; Eguchi Y; Wu C; Tanaka Y; Gane E; Tanwandee T; Cheung R; Yuen MF; Lee HS; Yu ML; Kao JH; Yang HI; Nguyen MH
    Hepatol Int; 2021 Feb; 15(1):71-81. PubMed ID: 33394321
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Progression Rates by Age, Sex, Treatment, and Disease Activity by AASLD and EASL Criteria: Data for Precision Medicine.
    Park J; Le AK; Tseng TC; Yeh ML; Jun DW; Trinh H; Wong GLH; Chen CH; Peng CY; Kim SE; Oh H; Kwak MS; Cheung KS; Toyoda H; Hsu YC; Jeong JY; Yoon EL; Ungtrakul T; Zhang J; Xie Q; Ahn SB; Enomoto M; Shim JJ; Cunningham C; Jeong SW; Cho YK; Ogawa E; Huang R; Lee DH; Takahashi H; Tsai PC; Huang CF; Dai CY; Tseng CH; Yasuda S; Kozuka R; Li J; Wong C; Wong CC; Zhao C; Hoang J; Eguchi Y; Wu C; Tanaka Y; Gane E; Tanwandee T; Cheung R; Yuen MF; Lee HS; Yu ML; Kao JH; Yang HI; Nguyen MH
    Clin Gastroenterol Hepatol; 2022 Apr; 20(4):874-885.e4. PubMed ID: 34089852
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term follow-up of cumulative incidence of hepatocellular carcinoma in hepatitis B virus patients without antiviral therapy.
    Jiang XY; Huang B; Huang DP; Wei CS; Zhong WC; Peng DT; Huang FR; Tong GD
    World J Gastroenterol; 2021 Mar; 27(11):1101-1116. PubMed ID: 33776376
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antiviral Therapy Reduces Risk of Cirrhosis in Noncirrhotic HBV Patients Among 4 Urban Safety-Net Health Systems.
    Wong RJ; Jain MK; Therapondos G; Niu B; Kshirsagar O; Thamer M
    Am J Gastroenterol; 2021 Jul; 116(7):1465-1475. PubMed ID: 33661148
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hepatocellular carcinoma incidence in noncirrhotic patients with chronic hepatitis B and patients with cirrhosis of all etiologies.
    Do AL; Wong CR; Nguyen LH; Nguyen VG; Trinh H; Nguyen MH
    J Clin Gastroenterol; 2014 Aug; 48(7):644-9. PubMed ID: 24201999
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reduced Incidence of Hepatocellular Carcinoma in Cirrhotic and Noncirrhotic Patients With Chronic Hepatitis B Treated With Tenofovir-A Propensity Score-Matched Study.
    Nguyen MH; Yang HI; Le A; Henry L; Nguyen N; Lee MH; Zhang J; Wong C; Wong C; Trinh H
    J Infect Dis; 2019 Jan; 219(1):10-18. PubMed ID: 29982737
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patients with chronic hepatitis B treated with oral antiviral therapy retain a higher risk for HCC compared with patients with inactive stage disease.
    Cho JY; Paik YH; Sohn W; Cho HC; Gwak GY; Choi MS; Lee JH; Koh KC; Paik SW; Yoo BC
    Gut; 2014 Dec; 63(12):1943-50. PubMed ID: 24615378
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Risk analysis for hepatocellular carcinoma in patients with chronic hepatitis B-associated cirrhosis complicated by type 2 diabetes mellitus: a 5-year prospective cohort study].
    Tang C; Hu C; Zhou Y; Song Y; Li M; Liao M; Sun J; Zhong C; Zhou L; Lin Z; Zhou Y
    Nan Fang Yi Ke Da Xue Xue Bao; 2021 Mar; 41(3):313-318. PubMed ID: 33849820
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of overall survival between antiviral-induced viral suppression and inactive phase chronic hepatitis B patients.
    Cho YY; Lee JH; Chang Y; Nam JY; Cho H; Lee DH; Cho EJ; Lee DH; Yu SJ; Lee JM; Kim YJ; Yoon JH
    J Viral Hepat; 2018 Oct; 25(10):1161-1171. PubMed ID: 29741286
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gaps and Disparities in Chronic Hepatitis B Monitoring and Treatment in the United States, 2016-2019.
    Pham TTH; Toy M; Hutton D; Thompson W; Conners EE; Nelson NP; Salomon JA; So S
    Med Care; 2023 Apr; 61(4):247-253. PubMed ID: 36893410
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term outcomes of chronic hepatitis B virus infection in the era of antiviral therapy in Korea.
    Park YH; Kim BK; Kim JK; Kim HC; Kim DY; Park JY; Han KH; Kim SU; Shin SH; Hahn KY; Ahn SH
    J Gastroenterol Hepatol; 2014 May; 29(5):1005-11. PubMed ID: 24325579
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The risk of hepatocellular carcinoma within and beyond the first 5 years of entecavir in Korean patients with chronic hepatitis B.
    Kim BG; Park NH; Lee SB; Jeon S; Park JH; Jung SW; Jeong ID; Bang SJ; Shin JW
    Liver Int; 2018 Dec; 38(12):2269-2276. PubMed ID: 30052303
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatocellular carcinoma prediction beyond year 5 of oral therapy in a large cohort of Caucasian patients with chronic hepatitis B.
    Papatheodoridis GV; Sypsa V; Dalekos GN; Yurdaydin C; Van Boemmel F; Buti M; Calleja JL; Chi H; Goulis J; Manolakopoulos S; Loglio A; Voulgaris T; Gatselis N; Keskin O; Veelken R; Lopez-Gomez M; Hansen BE; Savvidou S; Kourikou A; Vlachogiannakos J; Galanis K; Idilman R; Esteban R; Janssen HLA; Berg T; Lampertico P
    J Hepatol; 2020 Jun; 72(6):1088-1096. PubMed ID: 31981727
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Four-year entecavir therapy reduces hepatocellular carcinoma, cirrhotic events and mortality in chronic hepatitis B patients.
    Su TH; Hu TH; Chen CY; Huang YH; Chuang WL; Lin CC; Wang CC; Su WW; Chen MY; Peng CY; Chien RN; Huang YW; Wang HY; Lin CL; Yang SS; Chen TM; Mo LR; Hsu SJ; Tseng KC; Hsieh TY; Suk FM; Hu CT; Bair MJ; Liang CC; Lei YC; Tseng TC; Chen CL; Kao JH;
    Liver Int; 2016 Dec; 36(12):1755-1764. PubMed ID: 27634134
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-World Effectiveness From the Asia Pacific Rim Liver Consortium for HBV Risk Score for the Prediction of Hepatocellular Carcinoma in Chronic Hepatitis B Patients Treated With Oral Antiviral Therapy.
    Yang HI; Yeh ML; Wong GL; Peng CY; Chen CH; Trinh HN; Cheung KS; Xie Q; Su TH; Kozuka R; Lee DH; Ogawa E; Zhao C; Ning HB; Huang R; Li J; Zhang JQ; Ide T; Xing H; Iwane S; Takahashi H; Wong C; Wong C; Lin CH; Hoang J; Le A; Henry L; Toyoda H; Ueno Y; Gane EJ; Eguchi Y; Kurosaki M; Wu C; Liu C; Shang J; Furusyo N; Enomoto M; Kao JH; Yuen MF; Yu ML; Nguyen MH
    J Infect Dis; 2020 Jan; 221(3):389-399. PubMed ID: 31550363
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Higher risk of hepatocellular carcinoma in chronic hepatitis B vs chronic hepatitis C after achievement of virologic response.
    Kim GA; Han S; Kim HD; An J; Lim YS
    J Viral Hepat; 2017 Nov; 24(11):990-997. PubMed ID: 28499070
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reduced risk of hepatocellular carcinoma by achieving a subcirrhotic liver stiffness through antiviral agents in hepatitis B virus-related advanced fibrosis or cirrhosis.
    Kim BS; Seo YS; Kim YS; Lee CH; Lee HA; Um SH; Yoo JJ; Kim SG; Suh SJ; Jung YK; Ahn SH; Han KH; Yim HJ; Kim SU;
    J Gastroenterol Hepatol; 2018 Feb; 33(2):503-510. PubMed ID: 28666070
    [TBL] [Abstract][Full Text] [Related]  

  • 18. One-year Fibrosis-4 index helps identify minimal HCC risk in non-cirrhotic chronic hepatitis B patients with antiviral treatment.
    Tseng TC; Choi J; Nguyen MH; Peng CY; Siakavellas S; Papatheodoridis G; Wang CC; Lim YS; Lai HC; Trinh HN; Wong C; Wong C; Zhang J; Li J; Kao JH
    Hepatol Int; 2021 Feb; 15(1):105-113. PubMed ID: 33547557
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatitis B core-related antigen predicts disease progression and hepatocellular carcinoma in hepatitis B e antigen-negative chronic hepatitis B patients.
    Kaneko S; Kurosaki M; Inada K; Kirino S; Hayakawa Y; Yamashita K; Osawa L; Sekiguchi S; Higuchi M; Takaura K; Maeyashiki C; Tamaki N; Yasui Y; Itakura J; Takahashi Y; Tsuchiya K; Nakanishi H; Izumi N
    J Gastroenterol Hepatol; 2021 Oct; 36(10):2943-2951. PubMed ID: 34057248
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association Between Fatty Liver and Cirrhosis, Hepatocellular Carcinoma, and Hepatitis B Surface Antigen Seroclearance in Chronic Hepatitis B.
    Li J; Yang HI; Yeh ML; Le MH; Le AK; Yeo YH; Dai CY; Barnett S; Zhang JQ; Huang JF; Trinh HN; Wong C; Wong C; Hoang JK; Cheung R; Yu ML; Nguyen MH
    J Infect Dis; 2021 Jul; 224(2):294-302. PubMed ID: 33249474
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.